J.ophthalmol.(Ukraine).2021;5:84-87.

http://doi.org/10.31288/oftalmolzh202158487

Received: 22 March 2021; Published on-line: 23 October 2021


Chloroquine maculopathy in a patient on long-term chloroquine therapy for pulmonary sarcoidosis: a case report

N. V. Malachkova, T. Ie. Kozlova

National Pirogov Memorial Medical University, Vinnytsya, Optimal Vision Center; Vinnytsia (Ukraine)

E-mail: malachkovanataliia@gmail.com

TO CITE THIS ARTICLE: Malachkova NV, Kozlova TIe. Chloroquine maculopathy in a patient on long-term chloroquine therapy for pulmonary sarcoidosis: a case report. J.ophthalmol.(Ukraine).2021;5:84-7.  http://doi.org/10.31288/oftalmolzh202158487


The article is on an important subject, chloroquine maculopathy associated with long-term use of chloroquine. Given that chloroquine has been widely used for the treatment of COVID-19, it is important to accumulate data on adverse reaction to chloroquine and its derivatives, especially in the populations of Europe where the practice of using these antimalarials was not so common as in Asia and Africa. The reported case exemplifies possible ocular side effects in patients on long-term use of chloroquine (Delagil).

Key words: chloroquine maculopathy, case, diagnosis, treatment, mistakes


References

1. Sharma OM. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol. 1998 Sep;55(9):1248-54. 

Crossref  PubMed

2. Lisitsyna TA, Kosheleva NM. [Antimalarial drugs in the therapy of systemic lupus erythematosus: present, past and future]. Sovremennaia revmatologiia. 2010;2:81-7. Russian.  

Crossref

3. Mehra MR, Ruschitzka F, Patel AM. Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020 Jun 5. 

Crossref

4. Marmor MF, Kellner U, Lai TY, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016 Jun;123(6):1386-94.  

Crossref  PubMed

5. World Health Organization. Medicines: safety of medicines—adverse drug reactions. Fact sheet no. 293. October 2008. Available at: http://www.who.int/mediacentre/factsheets/fs293/en/. 

6. Kiely PDW, Brown AK, Edwards CJ, et al. Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology (Oxford). 2009 Jul;48(7):765-72. 

Crossref  PubMed

7. Avina-Zubieta JA, Galiando-Rodrignez G, Newman S, et al. Long term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis. 1998 Oct;57(10):582-7. 

Crossref  PubMed

8. Ruiz-Irastozza G, Ramos-Casals M, Brito-Zeron P, Khamastra MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010 Jan;69(1):20-8. 

Crossref  PubMed

9. Rynes RI. Antimalarial drugs in the treatment of rheumatoiogical diseases. Brit J Rheum. 1997 Jul;36(7):799-805. 

Crossref  PubMed

10. Cambiaggi A. Unusual ocular lesions in a case of systemic lupus erythematosus. AMA Arch Ophthalmol. 1957 Mar;57(3):451-3. 

Crossref  PubMed

11. Kazaryan AA, Ponomareva EN. [Ophthalmic manifestations of chloroquine toxicity: a case report]. Klinicheskaia praktika. 2011;2:12-21. Russian. Crossref

12. Yam JC, Kwok AK. Ocular toxicity of hydroxychloroquine. Hong Kong Med J. 2006 Aug;12(4):294-304. 

13. Tehrani R, Ostrowski RA, Hariman R, Jay WM. Ocular toxicity of hydroxychloroquine. Semin Ophthalmology. May-Jun 2008;23(3):201-9. 

Crossref  PubMed

14. Shearer RV, Dubois EI. Ocular changes induced by long-term hydroxychloroquine (Plaquenil) therapy. Am J Ophtalmol. 1967 Aug;64(2):245-52.  

Crossref

15. Duncker G, Schmiederer M, Bredehorn T. Chloroquine-induced lipidosis in the rat retina: a functional and morphological study. Opthalmologica. 1995;209(2):79-83. 

Crossref  PubMed